Paola Canzano

Paola Canzano

Auto-generated profile, based on publicly available information

Paola Canzano

Centro Cardiologico Monzino IRCCS, Milan, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Atherosclerosis
Verified
Journal Article
Closed access
MLMaria Giovanna Lupo
Maria Giovanna Lupo
ABAlessandro Bressan
Alessandro Bressan
MDMaristella Donato
Maristella Donato
PCPaola Canzano
Paola Canzano
MCMarina Camera
Marina Camera
Nicola FerriNicola Ferri
Nicola Ferri

1 January 2015 in Thrombosis and Haemostasis
Verified
Journal Article
Closed access
PDF file
PCPaola Canzano
Paola Canzano
LRLaura Rossetti
Laura Rossetti
Nicola FerriNicola Ferri
Nicola Ferri
ABAlessandra Balduini
Alessandra Balduini
VAVittorio Abbonante
Vittorio Abbonante
MCMarina Camera
Marina Camera
Tissue factor (TF), the main activator of the blood coagulation cascade, has been shown to be expressed by platelets. Despite the evidence that both megakaryocytes and platelets express TF mRNA, and that platelets can make de novo protein synthesis, the main mechanism thought to be responsible for the presence of TF within platelets is through the uptake of TF positive microparticles. In this study we assessed 1) whether human megakaryocytes synthesise TF and transfer it to platelets and 2) the contribution of platelet-TF to the platelet hemostatic capacity. In order to avoid the cross-talk with circulating microparticles, we took advantage from an in vitro cultured megakaryoblastic cell line (Meg-01) able to differentiate into megakaryocytes releasing platelet-like particles. We show that functionally active TF is expressed in human megakaryoblasts, increased in megakaryocytes, and is transferred to a subset of shed platelets where it contributes to clot formation. These data were all confirmed in human CD34pos- derived megakaryocytes and in their released platelets. The effect of TF silencing in Meg-megakaryoblasts resulted in a significant reduction of TF expression in these cells and also in Meg-megakaryocytes and Meg-platelets. Moreover, the contribution of platelet-TF to the platelet hemostatic capacity was highlighted by the significant delay in the kinetic of thrombin formation observed in platelets released by TF-silenced megakaryocytes. These findings provide evidences that TF is an endogenously synthesised protein that characterises megakaryocyte maturation and that it is transferred to a subset of newly-released platelets where it is functionally active and able to trigger thrombin generation. * These authors contributed equally to this article.

31 March 2012 in Thrombosis Research
Verified
Journal Article
Closed access
PDF file
MCMarina Camera
Marina Camera
MBMarta Brambilla
Marta Brambilla
LFLaura Facchinetti
Laura Facchinetti
PCPaola Canzano
Paola Canzano
RSRita Spirito
Rita Spirito
ETElena Tremoli
Elena Tremoli

26 September 2015 in Seminars in Thrombosis and Hemostasis
Verified
Journal Article
Closed access
VTVincenzo Toschi
Vincenzo Toschi
MBMarta Brambilla
Marta Brambilla
MLMaddalena Lettino
Maddalena Lettino
LRLaura Rossetti
Laura Rossetti
PCPaola Canzano
Paola Canzano
MCMarina Camera
Marina Camera
The contribution of vessel wall-derived tissue factor (TF) to atherothrombosis is well established, whereas the pathophysiological relevance of the blood-borne TF is still a matter of debate, and controversies on the presence of platelet-associated TF still exist. In the past 15 years, several studies have documented the presence of TF in human platelets, the capacity of human platelets to use TF mRNA to make de novo protein synthesis, and the increase in the percentage of TF positive platelets in pathological conditions such as coronary artery disease (CAD). The exposure of vessel wall-derived TF at the site of vascular injury would play its main role in the initiation phase, whereas the blood-borne TF carried by platelets would be involved in the propagation phase of thrombus formation. More recent data indicate that megakaryocytes are committed to release into the bloodstream a well-defined number of TF-carrying platelets, which represents only a fraction of the whole platelet population. These findings are in line with the evidence that platelets are heterogeneous in their functions and only a subset of them is involved in the hemostatic process. In this review we summarize the existing knowledge on platelet associated TF and speculate on its relevance to physiology and to atherothrombosis and CAD.

23 June 2017 in Platelets
Verified
Journal Article
Open access
MBMarta Brambilla
Marta Brambilla
LRLaura Rossetti
Laura Rossetti
CZChiara Zara
Chiara Zara
PCPaola Canzano
Paola Canzano
PGPeter L.A. Giesen
Peter L.A. Giesen
MCMarina Camera
Marina Camera
Tissue factor (TF), the key activator of the blood coagulation cascade and of thrombus formation, is also expressed by circulating human platelets. Despite the documented in-depth characterization of platelet TF carried out in the past 15 years, some authors still fail to identify TF in platelets, especially when assessment in platelet-rich plasma (PRP) or washed platelets is carried out. This study aims to extend the characterization of the subset of TF-positive platelets in PRP from healthy subjects and to verify how different centrifugation forces, used to prepare the PRP, could affect the analysis of TF-positive platelets. Data indicate that large-size platelets express significantly higher amount of TF compared to small-size cells, in terms of both TF protein and TF mRNA. Upon stimulation, large platelets readily expose on the cell membrane TF, which is functionally active, i.e., able to generate factor Xa (FXa) as well as thrombin. By contrast, TF activity in small platelets is almost completely quenched by tissue factor pathway inhibitor (TFPI), becoming indeed detectable only after treatment with an anti-TFPI antibody. Our data highlight that particular attention must be paid to the preparation and collection of the PRP since such preanalytical variables may influence the platelet recovery and in turn affect subsequent analysis, whether it is flow cytometry, functional activity tests, proteome, or transcriptome analysis. Indeed, the TF-positive subset of large platelets can easily be lost if centrifugation protocols are not optimized, thus erroneously leading to a false-negative result.

18 January 2023 in Thrombosis Research
Verified
Journal Article
Open access
MBMarta Brambilla
Marta Brambilla
PCPaola Canzano
Paola Canzano
PVPatrizia Della Valle
Patrizia Della Valle
ABAlessia Becchetti
Alessia Becchetti
MCMaria Conti
Maria Conti
MCMarina Camera
Marina Camera
Studies exploring alterations in blood coagulation and platelet activation induced by COVID-19 vaccines are not concordant. We aimed to assess the impact of four COVID-19 vaccines on platelet activation, coagulation, and inflammation considering also the immunization dose and the history of SARS-CoV-2 infection. TREASURE study enrolled 368 consecutive subjects (161 receiving viral vector vaccines -ChAdOx1-S/Vaxzevria or Janssen- and 207 receiving mRNA vaccines -Comirnaty/Pfizer-BioNTech or Spikevax/Moderna). Blood was collected the day before and 8 ± 2 days after the vaccination. Platelet activation markers (P-selectin, aGPIIbIIIa and Tissue Factor expression; number of platelet-monocyte and -granulocyte aggregates) and microvesicle release were analyzed by flow cytometry. Platelet thrombin generation (TG) capacity was measured using the Calibrated Automated Thrombogram. Plasma coagulation and inflammation markers and immune response were evaluated by ELISA. Vaccination did not induce platelet activation and microvesicle release. IL-6 and CRP levels (+30%), D-dimer, fibrinogen and F1+2 (+13%, +3.7%, +4.3%, respectively) but not TAT levels significantly increased upon immunization with all four vaccines, with no difference among them and between first and second dose. An overall minor post-vaccination reduction of aPC, TM and TFPI, all possibly related to endothelial function, was observed. No anti-PF4 seroconversion was observed. This study showed that the four COVID-19 vaccines administered to a large population sample induce a transient inflammatory response, with no onset of platelet activation. The minor changes in clotting activation and endothelial function might be potentially involved at a population level in explaining the very rare venous thromboembolic complications of COVID-19 vaccination.